Expanded Access for AG-221

NO_LONGER_AVAILABLE

Conditions studied: Acute Myeloid Leukemia

In brief

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Key facts

Study ID

NCT03723057

Run by

Celgene

Last updated by the study team

2019-10-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Celgene — Summit, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.